62% alive at 3 years (OS rate KM estimate)^1,2*

OS in the ~3-year median study follow-up

Tick marks represent censored patients. Subjects who were alive by the analysis data cutoff date were censored at their last contact date prior to the data cutoff date with the exception that subjects known to be alive or determined to have died after the data cutoff date were censored at the data cutoff date.²

Pinch to zoom

*Kaplan-Meier estimate in the efficacy-evaluable population.²

• OS is defined as the time from the date of infusion to the date of death from any cause²
• In the primary analysis, median OS was not reached (95% CI: 24, NE) at a median follow-up of 12.3 months³
• OS was a secondary endpoint of the ZUMA-2 phase 2, single-arm, open-label study and was not the primary objective of the study³
• OS data are not included in the USPI. OS data are descriptive and should be carefully interpreted
• TECARTUS^® is currently under accelerated approval for R/R MCL based on overall response rate and durability of response. Further clinical studies will be conducted¹

48% progression-free at 3 years (PFS rate KM estimate)^4†

PFS in the ~3-year median study follow-up

Tick marks represent censored patients. Subjects not meeting the criteria (ie, patients who experienced disease progression or death) by the analysis data cutoff date were censored at their last evaluable disease assessment date prior to the data cutoff date or new anticancer therapy (including SCT) start date, whichever was earlier.⁴

Pinch to zoom

^†Kaplan-Meier estimate in the efficacy-evaluable population.⁴

• PFS was a secondary endpoint of the ZUMA-2 phase 2, single-arm, open-label study and was not the primary objective of the study³
• PFS data are not included in the USPI. PFS data are descriptive and should be carefully interpreted
• TECARTUS is currently under accelerated approval for R/R MCL based on overall response rate and durability of response. Further clinical studies will be conducted¹